{"success":true,"data":{"pressRelease":{"id":"1591","rtpr_id":"nGNX5SK456","ticker":"AVCN","exchange":"TSX","all_tickers":["AVCN"],"title":"Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics","author":"Globe Newswire","published_at":"2026-04-20T13:00:01.449Z","article_body":"An established forum for evidence-based clinical discussion, interdisciplinary\ndialogue, and patient considerations\nEvent is expanded to two days, live and virtual on June 11-12, 2026, at the\nMaRS Discovery District, Toronto\n\nTORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or\nthe “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical\ncompany focused on the development, manufacturing and commercialisation of\nplant-derived cannabinoid-based products will host its 6(th) annual clinical\nsymposium on Cannabinoid-based Therapeutics – “From Emerging Evidence to\nClinical Practice” on June 11-12, 2026 at the MaRS Discovery District,\nToronto.\n\nREGISTER NOW\n(https://www.globenewswire.com/Tracker?data=twceWxtSuLBN3Iu4Xs9Cx7AD_j7oPIcec_yipIny2OHsC7urOhuPI1oknV70RxoPz6PSigLbrq0KFxq9uUZtOAYcQ-WF1xkpCTPcfCxwH7vwiAfNpVvGeSHTRlRaucSEm5wZnEBVhlIJSp7K-752uXIDkledIY4DEFcNaqgky-_rvNps0meDboCTB-0qHz6l)\n\n\nREGISTER NOW\n(https://www.globenewswire.com/Tracker?data=twceWxtSuLBN3Iu4Xs9Cx3Ws5hLB2DhVWujt7WSJJGTLFweh8ycwb8qD1fobjE0y1o5f7i_S9Y4p-dnn_IIJLmIElPA-2ErZ6_iqYvQcNR-6DnLJoX-8w8UCySUKmxX4uLWqlvYyiN-Whlb7jl59lbOEU5xLS6WRFYRJrMBosnqnlvqtZyUaw3QDYlL-GQe8)\n\nResearchers, industry professionals, and healthcare practitioners from across\nCanada and internationally will convene for an expanded two-day program\nfocused on current evidence and clinical considerations in cannabinoid\ntherapeutics. Over successive years, the symposium has brought together\nvarious physicians, researchers, pharmacists, and healthcare professionals\nfrom academic and clinical settings to support clinical dialogue and research\nexchange related to patient care.\n\nThe 2026 symposium will feature an expanded agenda including new research\nfindings, case-based clinical discussions, and multidisciplinary panels\nfocused on prescribing practices, treatment planning, and patient management.\nThe program reflects ongoing interest in the integration of cannabinoid-based\ntherapies into clinical practice, alongside recognition of existing evidence\ngaps and variability in clinical guidance. Speakers will include clinicians\nand researchers representing disciplines such as primary care, pain\nmanagement, neurology and psychiatry across various therapeutic needs and\npatient populations.\n\n“This symposium provides clinicians and researchers an opportunity to review\nemerging evidence, share real-world clinical experience, and examine the role\nof cannabinoid-based therapies in patient care,” said Karolina Urban,\nExecutive Vice President of Medical Affairs at Avicanna. “This year’s\nprogram places a deliberate focus on areas that are often underrepresented,\nincluding women’s health, evidence-informed care for veterans, and the\ntranslation of research into practical clinical decision making.”\n\nIn addition to live sessions, this event will be recorded and made available\nthrough the Avicenna Academy\n(https://www.globenewswire.com/Tracker?data=P369R8TiS9RnXJdSc-rxBzs83_th2tEeC04mxXqY77Wdgkwbl_G0JqY2BVx1WbcXa4gI62Ve2iBzoA4FE8SflNq9VdD888mbaJD9D_67wYFkRZ3RtjBY9zmgWzMVpleAWHr-baEGmNN52-4LD0VWQp8A48EsBRve6TFbqmNyNmJPtV3V0v22xHZNmhrFY1YgN_1p06Zq0DFak4VCm4T2jw==),\nour growing library of clinical resources, recorded lectures, and educational\nmaterials designed to support.\n\nHealthcare professionals interested in attending or showcasing their research\nat the symposium are invited to register online or submit posters for\nconsideration by the organizing committee.\n\nSUBMIT A POSTER\n(https://www.globenewswire.com/Tracker?data=FcDZnHkFJS0Qn97mGGsQV3EFLzZl0_8K4_YncbU0ijTh0ha5HY2ba1djJpZi_p-ezTGR5yzVRetyq3Vd8d9_0GezmH4mCcp1uJy6pYF42AXdAvjser1x-ZmZHhREL-aOGOXiYXsL2luJ85M-AQY2xNCJ25QSOYQpQPmgGCqaSlwY7s_N1hEziSukS4Qiijst79MKWe_nW6PYW-To7X9Lx6bvuLJ9cKFs-P-f5T-LYsOWwmvcf0K7FUbHyoI9FwAo)\n\nFeatured Speakers and Topics\n\n Speaker Topic \n Dr. James MacKillop, PhD, CPsych, FCAHS McMaster University, St. Joseph's Healthcare Hamilton State of the evidence for medical cannabis in Canada \n Dr. Daniel Bear, PhD Humber Polytechnic Symptoms & Science: What we know about cannabinoids, where evidence is lacking, and why absence of evidence isn’t evidence of absence. \n Dr. Evan Lewis, MD, FRCPC University of Toronto, Pediatrics Clinical Workshop: Prescribing medical cannabis — practical approaches to initiation, titration, and patient management \n Dr. Matthew Hill, PhD University of Calgary Neurobiology, hyperarousal, and clinical considerations \n Dr. Zachary Walsh, PhD, RPsych University of British Columbia Clinical evidence for harm reduction and substitution \n TBD – Veterans & Veteran Support Groups Veteran and patient perspectives — clinical needs, outcomes, and barriers to care \n Dr. Hance Clarke, MD, PhD, FRCPC Toronto General Hospital, University Health Network Evidence from RWE study and next steps in pain-related medical cannabis prescription. \n Dr. Elizabeth Thompson, PhD, MSc University of Saskatchewan Brain injury, cannabinoids, and the endocannabinoid system \n Michael Koehn, MACP, RCC, CHPC Cannsolve The Maverick Medical Cannabis Project: Insights and implementation of a novel intervention for the overdose crisis. \n Dr. Dilshaan Panjwani, MD BC Cancer Medical Cannabis Extracts for Cancer-Related Symptoms: Results of an innovative n-of-1 clinical trial \n Erin Mignault, NP, MSc June Health, KixCare, Care2Talk Health Clinical Workshop on Women's Health: Menopause — pathophysiology and the role of cannabinoid-based therapies \n Dr. Luiza Marouelli, MD, OB-GYN Santé Cannabis Cannabinoids in Gynecologic Care: Real-World Applications and Clinical Experience \n \n\nAbout the Symposium\nThe Annual Clinical Symposium on Cannabinoid Therapeutics is a national\nscientific forum dedicated to advancing evidence-based education, research,\nand clinical practice in cannabinoid medicine. The symposium brings together\nhealthcare professionals across disciplines to examine emerging data, discuss\nclinical applications, and address limitations in current evidence related to\ncannabinoid-based therapies.\n\nAbout Avicanna:\nAvicanna is an international biopharmaceutical company specializing in the\ncommercialization of proprietary and evidence-based cannabinoid-based products\nfor the global medical and pharmaceutical market segments. Avicanna has\nestablished scientific and medical affairs platforms that support its four\ncommercial stage business pillars and have resulted in the commercialization\nof more than fifty finished products.\n* Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse\nrange of proprietary products including oral, sublingual, topical, and\ntransdermal deliveries with varying ratios of cannabinoids, supported by\nongoing patient and medical community education. RHO Phyto™ is an\nestablished brand in Canada currently available nationwide across several\nchannels and expanding into new international markets.\n\n* Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis\ncare platform formed with the aim to better serve medical cannabis patients’\nneeds and enhance the medical cannabis patients’ journey. MyMedi.ca is\noperated by Northern Green Canada Inc. and features a diverse portfolio of\nproducts and bilingual pharmacist-led patient support programs. MyMedi.ca also\nprovides specialty services to distinct patient groups such as veterans and\ncollaborates with public and private payers for adjudication and\nreimbursement. MyMedi.ca provides educational resources to the medical\ncommunity to facilitate the incorporation of medical cannabis into health care\nregimens.\n\n* Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform,\nvertical integration, and real-world evidence, Avicanna has developed a\npipeline of proprietary, indication-specific cannabinoid-based candidates that\nare in various stages of clinical development. These cannabinoid-based\ncandidates aim to address unmet needs in the areas of dermatology, chronic\npain, and various neurological disorders.\n\n* Active pharmaceutical ingredients (Aureus Santa Marta™): Active\npharmaceutical ingredients supplied by the Company’s majority owned\nsubsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage\nbusiness dedicated to providing various forms of high-quality CBD, THC and CBG\nto the Company’s international partners for use in the development and\nproduction of food, cosmetics, medical, and pharmaceutical products. SMGH also\nforms part of the Company’s supply chain and is a source of reliable input\nproducts for its consumer retail, medical cannabis, and pharmaceutical\nproducts globally.\nSOURCE Avicanna Inc. \n\nStay Connected \n\nFor more information about Avicanna, visit our website or contact Ivana\nMaric by email at ir@avicanna.com. \n\nCautionary Note Regarding Forward-Looking Information and Statements\n\nThis news release contains “forward-looking information” within the\nmeaning of applicable securities laws. Forward-looking information contained\nin this news release may be identified by the use of words such as, “may”,\n“would”, “could”, “will”, “likely”, “expect”,\n“anticipate”, “believe”, “intend”, “plan”, “forecast”,\n“project”, “estimate”, “outlook” and other similar expressions.\nForward-looking information contained in this news release includes, without\nlimitation, statements related to the Company’s future business operations,\nthe opinions or beliefs of management and future business goals. Although the\nCompany believes that the expectations and assumptions on which such forward\nlooking information is based are reasonable, undue reliance should not be\nplaced on the forward-looking information because the Company can give no\nassurance that they will prove to be correct. Actual results and developments\nmay differ materially from those contemplated by these statements.\nForward-looking information is subject to a variety of risks and uncertainties\nthat could cause actual events or results to differ materially from those\nprojected in the forward-looking information. Such risks and uncertainties\ninclude, but are not limited to current and future market conditions,\nincluding the market price of the common shares of the Company, and the risk\nfactors set out in the Company’s annual information form dated March 31,\n2026, filed with the Canadian securities regulators and available under the\nCompany’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news\nrelease are made as of the date of this release. The Company disclaims any\nintent or obligation to update any forward-looking information, whether as a\nresult of new information, future events or results or otherwise, other than\nas required by applicable securities laws.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/dff23be4-6d2a-4fbc-a561-e13c2438d17a\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c9abc2f4-efdc-40f6-921d-a5da048eda46)\nAvicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid\nTherapeutics \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dff23be4-6d2a-4fbc-a561-e13c2438d17a/en)\nAn established forum for evidence-based clinical discussion, interdisciplinary\ndialogue, and patient considerationsEvent is expanded to two days, live and\nvirtual on June 11-12, 2025, at the MaRS Discovery District, Toronto\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5SK456","title":"Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics","author":"Globe Newswire","ticker":"AVCN","created":"2026-04-20T13:00:01.449Z","tickers":["AVCN"],"exchange":"TSX","article_body":"An established forum for evidence-based clinical discussion, interdisciplinary\ndialogue, and patient considerations\nEvent is expanded to two days, live and virtual on June 11-12, 2026, at the\nMaRS Discovery District, Toronto\n\nTORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or\nthe “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical\ncompany focused on the development, manufacturing and commercialisation of\nplant-derived cannabinoid-based products will host its 6(th) annual clinical\nsymposium on Cannabinoid-based Therapeutics – “From Emerging Evidence to\nClinical Practice” on June 11-12, 2026 at the MaRS Discovery District,\nToronto.\n\nREGISTER NOW\n(https://www.globenewswire.com/Tracker?data=twceWxtSuLBN3Iu4Xs9Cx7AD_j7oPIcec_yipIny2OHsC7urOhuPI1oknV70RxoPz6PSigLbrq0KFxq9uUZtOAYcQ-WF1xkpCTPcfCxwH7vwiAfNpVvGeSHTRlRaucSEm5wZnEBVhlIJSp7K-752uXIDkledIY4DEFcNaqgky-_rvNps0meDboCTB-0qHz6l)\n\n\nREGISTER NOW\n(https://www.globenewswire.com/Tracker?data=twceWxtSuLBN3Iu4Xs9Cx3Ws5hLB2DhVWujt7WSJJGTLFweh8ycwb8qD1fobjE0y1o5f7i_S9Y4p-dnn_IIJLmIElPA-2ErZ6_iqYvQcNR-6DnLJoX-8w8UCySUKmxX4uLWqlvYyiN-Whlb7jl59lbOEU5xLS6WRFYRJrMBosnqnlvqtZyUaw3QDYlL-GQe8)\n\nResearchers, industry professionals, and healthcare practitioners from across\nCanada and internationally will convene for an expanded two-day program\nfocused on current evidence and clinical considerations in cannabinoid\ntherapeutics. Over successive years, the symposium has brought together\nvarious physicians, researchers, pharmacists, and healthcare professionals\nfrom academic and clinical settings to support clinical dialogue and research\nexchange related to patient care.\n\nThe 2026 symposium will feature an expanded agenda including new research\nfindings, case-based clinical discussions, and multidisciplinary panels\nfocused on prescribing practices, treatment planning, and patient management.\nThe program reflects ongoing interest in the integration of cannabinoid-based\ntherapies into clinical practice, alongside recognition of existing evidence\ngaps and variability in clinical guidance. Speakers will include clinicians\nand researchers representing disciplines such as primary care, pain\nmanagement, neurology and psychiatry across various therapeutic needs and\npatient populations.\n\n“This symposium provides clinicians and researchers an opportunity to review\nemerging evidence, share real-world clinical experience, and examine the role\nof cannabinoid-based therapies in patient care,” said Karolina Urban,\nExecutive Vice President of Medical Affairs at Avicanna. “This year’s\nprogram places a deliberate focus on areas that are often underrepresented,\nincluding women’s health, evidence-informed care for veterans, and the\ntranslation of research into practical clinical decision making.”\n\nIn addition to live sessions, this event will be recorded and made available\nthrough the Avicenna Academy\n(https://www.globenewswire.com/Tracker?data=P369R8TiS9RnXJdSc-rxBzs83_th2tEeC04mxXqY77Wdgkwbl_G0JqY2BVx1WbcXa4gI62Ve2iBzoA4FE8SflNq9VdD888mbaJD9D_67wYFkRZ3RtjBY9zmgWzMVpleAWHr-baEGmNN52-4LD0VWQp8A48EsBRve6TFbqmNyNmJPtV3V0v22xHZNmhrFY1YgN_1p06Zq0DFak4VCm4T2jw==),\nour growing library of clinical resources, recorded lectures, and educational\nmaterials designed to support.\n\nHealthcare professionals interested in attending or showcasing their research\nat the symposium are invited to register online or submit posters for\nconsideration by the organizing committee.\n\nSUBMIT A POSTER\n(https://www.globenewswire.com/Tracker?data=FcDZnHkFJS0Qn97mGGsQV3EFLzZl0_8K4_YncbU0ijTh0ha5HY2ba1djJpZi_p-ezTGR5yzVRetyq3Vd8d9_0GezmH4mCcp1uJy6pYF42AXdAvjser1x-ZmZHhREL-aOGOXiYXsL2luJ85M-AQY2xNCJ25QSOYQpQPmgGCqaSlwY7s_N1hEziSukS4Qiijst79MKWe_nW6PYW-To7X9Lx6bvuLJ9cKFs-P-f5T-LYsOWwmvcf0K7FUbHyoI9FwAo)\n\nFeatured Speakers and Topics\n\n Speaker Topic \n Dr. James MacKillop, PhD, CPsych, FCAHS McMaster University, St. Joseph's Healthcare Hamilton State of the evidence for medical cannabis in Canada \n Dr. Daniel Bear, PhD Humber Polytechnic Symptoms & Science: What we know about cannabinoids, where evidence is lacking, and why absence of evidence isn’t evidence of absence. \n Dr. Evan Lewis, MD, FRCPC University of Toronto, Pediatrics Clinical Workshop: Prescribing medical cannabis — practical approaches to initiation, titration, and patient management \n Dr. Matthew Hill, PhD University of Calgary Neurobiology, hyperarousal, and clinical considerations \n Dr. Zachary Walsh, PhD, RPsych University of British Columbia Clinical evidence for harm reduction and substitution \n TBD – Veterans & Veteran Support Groups Veteran and patient perspectives — clinical needs, outcomes, and barriers to care \n Dr. Hance Clarke, MD, PhD, FRCPC Toronto General Hospital, University Health Network Evidence from RWE study and next steps in pain-related medical cannabis prescription. \n Dr. Elizabeth Thompson, PhD, MSc University of Saskatchewan Brain injury, cannabinoids, and the endocannabinoid system \n Michael Koehn, MACP, RCC, CHPC Cannsolve The Maverick Medical Cannabis Project: Insights and implementation of a novel intervention for the overdose crisis. \n Dr. Dilshaan Panjwani, MD BC Cancer Medical Cannabis Extracts for Cancer-Related Symptoms: Results of an innovative n-of-1 clinical trial \n Erin Mignault, NP, MSc June Health, KixCare, Care2Talk Health Clinical Workshop on Women's Health: Menopause — pathophysiology and the role of cannabinoid-based therapies \n Dr. Luiza Marouelli, MD, OB-GYN Santé Cannabis Cannabinoids in Gynecologic Care: Real-World Applications and Clinical Experience \n \n\nAbout the Symposium\nThe Annual Clinical Symposium on Cannabinoid Therapeutics is a national\nscientific forum dedicated to advancing evidence-based education, research,\nand clinical practice in cannabinoid medicine. The symposium brings together\nhealthcare professionals across disciplines to examine emerging data, discuss\nclinical applications, and address limitations in current evidence related to\ncannabinoid-based therapies.\n\nAbout Avicanna:\nAvicanna is an international biopharmaceutical company specializing in the\ncommercialization of proprietary and evidence-based cannabinoid-based products\nfor the global medical and pharmaceutical market segments. Avicanna has\nestablished scientific and medical affairs platforms that support its four\ncommercial stage business pillars and have resulted in the commercialization\nof more than fifty finished products.\n* Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse\nrange of proprietary products including oral, sublingual, topical, and\ntransdermal deliveries with varying ratios of cannabinoids, supported by\nongoing patient and medical community education. RHO Phyto™ is an\nestablished brand in Canada currently available nationwide across several\nchannels and expanding into new international markets.\n\n* Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis\ncare platform formed with the aim to better serve medical cannabis patients’\nneeds and enhance the medical cannabis patients’ journey. MyMedi.ca is\noperated by Northern Green Canada Inc. and features a diverse portfolio of\nproducts and bilingual pharmacist-led patient support programs. MyMedi.ca also\nprovides specialty services to distinct patient groups such as veterans and\ncollaborates with public and private payers for adjudication and\nreimbursement. MyMedi.ca provides educational resources to the medical\ncommunity to facilitate the incorporation of medical cannabis into health care\nregimens.\n\n* Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform,\nvertical integration, and real-world evidence, Avicanna has developed a\npipeline of proprietary, indication-specific cannabinoid-based candidates that\nare in various stages of clinical development. These cannabinoid-based\ncandidates aim to address unmet needs in the areas of dermatology, chronic\npain, and various neurological disorders.\n\n* Active pharmaceutical ingredients (Aureus Santa Marta™): Active\npharmaceutical ingredients supplied by the Company’s majority owned\nsubsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage\nbusiness dedicated to providing various forms of high-quality CBD, THC and CBG\nto the Company’s international partners for use in the development and\nproduction of food, cosmetics, medical, and pharmaceutical products. SMGH also\nforms part of the Company’s supply chain and is a source of reliable input\nproducts for its consumer retail, medical cannabis, and pharmaceutical\nproducts globally.\nSOURCE Avicanna Inc. \n\nStay Connected \n\nFor more information about Avicanna, visit our website or contact Ivana\nMaric by email at ir@avicanna.com. \n\nCautionary Note Regarding Forward-Looking Information and Statements\n\nThis news release contains “forward-looking information” within the\nmeaning of applicable securities laws. Forward-looking information contained\nin this news release may be identified by the use of words such as, “may”,\n“would”, “could”, “will”, “likely”, “expect”,\n“anticipate”, “believe”, “intend”, “plan”, “forecast”,\n“project”, “estimate”, “outlook” and other similar expressions.\nForward-looking information contained in this news release includes, without\nlimitation, statements related to the Company’s future business operations,\nthe opinions or beliefs of management and future business goals. Although the\nCompany believes that the expectations and assumptions on which such forward\nlooking information is based are reasonable, undue reliance should not be\nplaced on the forward-looking information because the Company can give no\nassurance that they will prove to be correct. Actual results and developments\nmay differ materially from those contemplated by these statements.\nForward-looking information is subject to a variety of risks and uncertainties\nthat could cause actual events or results to differ materially from those\nprojected in the forward-looking information. Such risks and uncertainties\ninclude, but are not limited to current and future market conditions,\nincluding the market price of the common shares of the Company, and the risk\nfactors set out in the Company’s annual information form dated March 31,\n2026, filed with the Canadian securities regulators and available under the\nCompany’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news\nrelease are made as of the date of this release. The Company disclaims any\nintent or obligation to update any forward-looking information, whether as a\nresult of new information, future events or results or otherwise, other than\nas required by applicable securities laws.\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/dff23be4-6d2a-4fbc-a561-e13c2438d17a\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c9abc2f4-efdc-40f6-921d-a5da048eda46)\nAvicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid\nTherapeutics \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dff23be4-6d2a-4fbc-a561-e13c2438d17a/en)\nAn established forum for evidence-based clinical discussion, interdisciplinary\ndialogue, and patient considerationsEvent is expanded to two days, live and\nvirtual on June 11-12, 2025, at the MaRS Discovery District, Toronto\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-20T13:00:01.51712367Z","server_sent_at_ms":1776690001517},"received_at":"2026-04-20T13:00:01.571Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}